We are continuing to closely monitor manufacturing and supply chain resources around the world to help ensure our patients continue to receive their medicines. We do not anticipate any disruption to our medicine supply for patients as a result of COVID-19.
We understand your need to know more about the coronavirus. If you are on an AbbVie treatment, please speak with your doctor regarding any questions you may have. Your doctor can provide medical advice to address your individual needs.
Globally, AbbVie is donating $35 million to help support underserved communities and healthcare systems working to address the impact of the COVID-19 pandemic.
Organisations supported by our $35 million donation include:
• International Medical Corps to help create capacity to treat patients at overburdened hospitals in the U.S. AbbVie’s donation will support the creation and operation of 20 mobile field hospitals to expand available triage at existing facilities, improve patient flow and keep COVID-19 patients separated from other patients. These standalone mobile field hospitals are being built in U.S. hotspots.
• Direct Relief to provide equipment and supplies in the hardest-hit European countries. This support will enable the procurement and delivery of oxygen concentrators, ventilators and personal protective equipment to frontline healthcare workers and patients. The UK has been identified as one of the European countries to benefit from this work.
We continue to have a formal Grants & Donations application process for third sector groups and healthcare organisations to request funding for defined work and projects that qualify within our criteria. Please visit our Grants & Donations page to find out further information.
If you are a registered healthcare provider with questions about COVID-19 and AbbVie medications, patient assistance or adverse event reporting, please visit AbbVie's medical information website, www.abbviemedinfo.com.
Protecting our employees
AbbVie is focused on ensuring the safety of our employees while we
continue to make the vital medicines our patients depend on.
AbbVie has taken the following steps to protect health at work for our employees:
• All employees who have jobs that can be done remotely are now
working from home.
• For those people who need to be at an AbbVie facility to do their job, we’ve taken steps to limit exposure risk and keep our worksites as safe as possible.
• We support social distancing at all facilities where possible and encourage all employees to practice recommended safety measures.
• Enacted strict travel restrictions in accordance with UK Government guidance.
We will continue to closely monitor this evolving situation during this unprecedented global health crisis.
Enabling AbbVie workers to volunteer
We are supporting medically qualified and non-medically qualified staff, who are willing and able to, to volunteer either within the NHS or within their local communities.
AbbVie is also doubling the AbbVie Foundation match for COVID-19-related contributions by employees. Instead of the typical 1-1 match, the AbbVie Foundation will match $2 to every $1 employees donate to a qualified non-profit group or organisation.
AbbVie is constantly monitoring and taking precautions to protect the safety of our study participants, clinical trial site staff and our employees. We will continue to evaluate any local support our study participants may require to maintain their safe involvement in our clinical trials.
The Association of the British Pharmaceutical Industry (ABPI) is working closely with the Department of Health and Social Care and the NHS on how its members can best support the UK Government as plans evolve and we adapt to an ever-changing situation.
The ABPI, the Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), British Generic Manufacturers Association (BGMA) and the British In Vitro Diagnostic Association (BIVIDA) have issued a call to action on the UK life sciences industry’s commitment to fighting COVID-19 and supporting NHS patients. This is available here.
More detailed information on the industry response is available on
the ABPI website here.